General Biotechnology

A single paragraph can cost a generic drugmaker $50 million.
Thats not a metaphor. Its the kind of paper cut that turns into a cash woundafter a Paragraph IV filing triggers a patent dispute, and one badly drafted passage ends up being treated like a r…

At-risk launches arent a gamble anymoretheyre a math problem.
In pharma, the phrase at risk has long carried a hint of romantic defiance: a company ships product knowing litigation is unresolved, accepting that damagesor even an injunctioncould follow….

Ever wonder why a handful of new drug patents can seem to stretch an entire decade? The story youre often told is neat: follow-on innovation improves outcomes, competition arrives when the science is ready.
But the realityespecially in periods leadin…

Most pharma patent challenges are treated like a last resort. Thats a mistake.
Heres the uncomfortable truth: when a method of use patent is weak, waiting to attack it is usually the most expensive optioneven if you ultimately win.
In a recent DrugPate…

The 180-Day Exclusivity Trap: Why Being First Still Doesnt Pay
In generic drug markets, everyone talks about the 180-day exclusivity clockbecause it sounds like a straight line to pricing power, market share, and profits.
But the reality is more compli…

Most companies treat patent settlements like a business-as-usual off-ramp. Thats a mistake. Heres the math behind why.
In pharma, weve all seen the playbook: a brand challenges a generic (or vice versa), litigation drags on, and somewhere along the way…

Your drugs patent fortress isnt as strong as it looksbecause device patents often crack first.
If you think the patent wars around pharmaceuticals are mainly battles over the active ingredientthe molecule, the formulation, the method-of-usethink again….

The Salt Change Trap: When a New Patent Buys You Nothing (But Still Costs You Everything)
In drug development, the most expensive word isnt pipeline. Its exclusivity. And nowhere is that more visible than in the growing saga of the salt changea seeming…

Pediatric exclusivity was designed to protect children. But in practice, it can become a liability for everyone else in the drug ecosystempatients included.
Thats the central tension explored in a new piece from DrugPatentWatch: the six-month fuse mech…

Bausch Health is fighting for more than cash flowits fighting for control of future cash flow.
In a recent development highlighted by DrugPatentWatch, Bausch Health Companies Inc. vs. Sun Pharmaceutical Industries Ltd. spotlights a familiar but high-st…